Jacquelyn Lahoud, MD
Infectious Disease · Brooklyn, NYNPI 1801114624
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,472 and has fallen 87.0% since, to $191 in 2025.
Across 254 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- AbbVie$912
- GSK$478
- Shionogi Inc$468
- Merck$368
- Novo Nordisk$332
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,304100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 31 | $1,035 |
| AbbVie(2 entities) | 42 | $912 |
| GSK | 15 | $478 |
| Shionogi Inc | 23 | $468 |
| Merck | 19 | $368 |
| Novo Nordisk | 15 | $332 |
| AstraZeneca | 11 | $311 |
| Johnson & Johnson | 15 | $290 |
| Pfizer | 13 | $288 |
| Paratek Pharmaceuticals, Inc. | 13 | $276 |
| Amarin Pharma, Inc. | 10 | $212 |
| Amgen | 7 | $177 |
| Aimmune Therapeutics, Inc. | 5 | $146 |
| Intersect ENT, Inc. | 1 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $141 |
| Lilly USA, LLC | 7 | $123 |
| Teva Pharmaceuticals USA, Inc. | 1 | $120 |
| Boston Scientific | 1 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $106 |
| Melinta Therapeutics, LLC | 3 | $63 |
| CSL Behring | 2 | $60 |
| Scilex Pharmaceuticals Inc. | 2 | $48 |
| Genentech USA, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Viiv Healthcare Company | 1 | $17 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,330 in reported general payments places this provider in the 85th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Brooklyn
- Andre BrutusBrooklyn$303K
- Joseph PaulBrooklyn$186K
- Marcus SandlingBrooklyn$157K
- Alan SteinBrooklyn$90K
- Jessica YagerBrooklyn$70K
- Yusuf AfacanBrooklyn$19K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.